1. Anti-infection
    Autophagy
  2. Bacterial
    Autophagy

Vancomycin hydrochloride 

Cat. No.: HY-17362 Purity: >98.0%
Data Sheet SDS Handling Instructions

Vancomycin hydrochloride is an antibiotic for the treatment of bacterial infections.

For research use only. We do not sell to patients.
Vancomycin hydrochloride Chemical Structure

Vancomycin hydrochloride Chemical Structure

CAS No. : 1404-93-9

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
250 mg $50 In-stock
1 g $60 In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

Other Forms of Vancomycin hydrochloride:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Vancomycin hydrochloride is an antibiotic for the treatment of bacterial infections.

In Vitro

Vancomycin is a large glycopeptide compound with a molecular weight of 1450 Da[1]. Vancomycin is a unique glycopeptide structurally unrelated to any currently available antibiotic. It also has a unique mode of action inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin is active against a large number of species of Gram-positive bacteria, such as Staphylococcus aureus, Staph. epidermidis, Str. agalactiae, Str. bovis, Str. mutans, viridans streptococci, enterococci[2].

In Vivo

Vancomycin is administered intravenously, with a standard infusion time of at least 1 h, to minimize infusion-related adverse effects. Subjects with normal creatinine clearance, vancomycin has an α-distribution phase of 30 min to 1 h and a β-elimination half-life of 6-12 h. The volume of distribution is 0.4–1 L/kg. The binding of vancomycin to protein ranges from 10% to 50%. Factors that affect the overall activity of vancomycin include its tissue distribution, inoculum size, and protein-binding effects[1]. Vancomycin treatment of infected mice is associated with improved clinical, diarrhea, and histopathology scores and survival during treatment[3].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01427842 The Canberra Hospital Vancomycin Therapy August 2011 Phase 2
NCT02096536 Universitaire Ziekenhuizen Leuven Neonatal Infection April 2014 Phase 4
NCT02051595 University of Florida Infection April 2014 Early Phase 1
NCT01623817 Samsung Medical Center Infection June 2012
NCT03046901 Ochsner Health System Primary Sclerosing Cholangitis|Post- Orthotopic Liver Transplantation December 7, 2016
NCT00861887 William Beaumont Hospitals|Beaumont Hospital Clostridium Difficile Colitis February 2009
NCT02631408 Orthopedic Hospital Vienna Speising Spinal Fusion Acquired August 2015 Phase 4
NCT02284126 Columbia University|Agency for Healthcare Research and Quality (AHRQ)|Cornell University|Icahn School of Medicine at Mount Sinai Infection|Surgery|Nervous System Diseases October 2014 Phase 3
NCT02020031 Mayo Clinic|Vidacare Corporation Arthropathy of Knee Joint December 2013 Phase 2|Phase 3
NCT01509339 Case Western Reserve University|Cystic Fibrosis Foundation Therapeutics Cystic Fibrosis|Methicillin-resistant Staphylococcus Aureus January 2012 Phase 1
NCT01619982 Stanford University Congenital Heart Diseases|Aortic Valve Disorder February 2012 Phase 4
NCT01322386 Stanford University Primary Sclerosing Cholangitis|Biliary Atresia May 2007 Phase 1
NCT01720940 National University Hospital, Singapore|Tan Tock Seng Hospital Infections Requiring Prolonged Duration (>10 Days) of Vancomycin October 2012
NCT02764359 CAMC Health System Infection|Sepsis|Obesity May 2016
NCT01802073 Stanford University Primary Sclerosing Cholangitis January 2012 Phase 3
NCT01290237 Boston Children’s Hospital Infection February 2011
NCT02663596 Drexel University|The Center for Pediatric Pharmacotherapy, LLC Pediatric Continuous Renal Replacement Therapy|Dialysis|Renal Failure January 2017 Phase 1
NCT02400112 University of Tennessee Fractures, Open|Surgical Wound Infection March 2015 Phase 4
NCT01786161 Massachusetts General Hospital MRSA - Methicillin Resistant Staphylococcus Aureus Infection September 2013 Phase 4
NCT02137668 Sacramento Pediatric Gastroenterology Primary Sclerosing Cholangitis|Biliary Atresia July 2010 Phase 1
NCT02839486 Bambino Gesù Hospital and Research Institute Congenital Heart Disease September 2016 Phase 2
NCT02210169 Murdoch Childrens Research Institute|Royal Children's Hospital|Mercy Hospital for Women, Australia Sepsis|Infection|Bacteremia September 2014
NCT01226992 University Health Network, Toronto Recurrent Clostridium Difficile Infection|Laboratory Confirmed Clostridium Difficile Infection October 2010 Phase 2|Phase 3
NCT01157533 M.D. Anderson Cancer Center Infection June 2010
NCT01346059 William Beaumont Hospitals Colitis April 2011
NCT01566422 Vanderbilt University Surgical Site Infection June 2012
NCT02374853 University of Alberta INFECTION March 2015 Phase 2
NCT01764750 Washington University School of Medicine Surgical Site Infection January 2013 Phase 1
NCT02443064 Zhejiang University|Shengjing Hospital|Tianjin Medical University Cancer Institute and Hospital|Qilu Hospital of Shandong University|First Affiliated Hospital, Sun Yat-Sen University|Guangzhou General Hospital of Guangzhou Military Command|The First Affiliated Hospital of Soochow University|The First Affiliated Hospital with Nanjing Medical University|Zhejiang Provincial Hospital of TCM|Second Affiliated Hospital, School of Medicine, Zhejiang University Blood Stream Infections|Endocarditis|MRSA January 2014 Phase 4
NCT02299882 Spectrum Health Hospitals Lumbar Pain August 2012
NCT02237859 Spectrum Health Hospitals Clostridium Difficile Infection August 2014 Phase 4
NCT01977989 University of Tennessee|Semmes-Murphey Foundation Wound Infection October 2013 Phase 4
NCT01975662 Singapore General Hospital|Singapore Clinical Research Institute Bacteremia Due to Staphylococcus Aureus January 2014 Phase 2
NCT02694458 Assistance Publique - Hôpitaux de Paris Methicillin-resistant Staphylococcal Infections February 23, 2016
NCT02605213 Tehran University of Medical Sciences Primary Sclerosing Cholangitis September 2015 Phase 4
NCT01818141 Hartford Hospital|Optimer Pharmaceuticals LLC Clostridium Difficile Infection October 17, 2012 Phase 4
NCT02692651 University of Michigan|Merck Sharp & Dohme Corp. Clostridium Difficile Infection (CDI) May 1, 2017 Phase 4
NCT02945241 Mayo Clinic Methicillin-resistant Staphylococcus Aureus|Sepsis|Critical Illness April 2014 Phase 1
NCT02254967 Astellas Pharma Europe Ltd.|Merck Sharp & Dohme Corp.|Astellas Pharma Inc Clostridium Difficile November 6, 2014 Phase 4
NCT03200093 Rochester General Hospital Clostridium Difficile Infection June 8, 2017 Phase 4
NCT02790996 PENTA Foundation|St George's, University of London|Institut National de la Santé Et de la Recherche Médicale, France|University of Tartu|Consorzio per Valutazioni Biologiche e Farmacologiche|University of Liverpool|Therakind limited|Bambino Gesù Hospital and Research Institute|Servicio Madrileño de Salud, Madrid, Spain|Aristotle University Of Thessaloniki|University of Edinburgh|SYNAPSE Research Management Partners S.L|European Commission Late Onset Neonatal Sepsis February 27, 2017 Phase 2
NCT00695903 Cubist Pharmaceuticals LLC Endocarditis, Bacterial|Infective Endocarditis September 2008 Phase 2
NCT01037192 Fraser Health Skin and Soft Tissue Infections March 2010
NCT01561469 Pfizer|University of Louisville|Henry Ford Hospital|Summa Health System|Sparrow Health System|Jackson Health System Methicillin-Resistant Staphylococcus Aureus (MRSA)|Hospital-Acquired Pneumonia November 2008
NCT01925066 Seoul National University Hospital|Seoul National University Bundang Hospital Pneumonia, Staphylococcal|Methicillin-Resistant Staphylococcus Aureus August 2013 Phase 2
NCT00138112 Memorial Sloan Kettering Cancer Center Streptococcal Sepsis|Hematologic Malignancies November 2003 Phase 3
NCT01983683 Actelion Clostridium Difficile Infection December 12, 2013 Phase 3
NCT01987895 Actelion Clostridium Difficile Infection March 27, 2014 Phase 3
NCT02607618 Motif Bio Skin Structures and Soft Tissue Infections November 2015 Phase 3
NCT02600611 Motif Bio Skin Structures and Soft Tissue Infections November 1, 2015 Phase 3
NCT01515020 Assistance Publique - Hôpitaux de Paris|Novartis Nosocomial Infection|Healthcare-associated Infection May 2012 Phase 3
NCT01162733 Christiana Care Health Services Infectious Disease July 2010
NCT00281281 National Taiwan University Hospital Extracorporeal Membrane Oxygenation December 2005 Phase 4
NCT01867138 Hospital Italiano de Buenos Aires Nosocomial Neonatal Sepsis March 2007 Phase 3
NCT02432807 Kurobe LLC Bacterial Conjunctivitis May 2015 Phase 3
NCT00295178 Cubist Pharmaceuticals LLC Cellulitis February 2006 Phase 4
NCT01199783 Ruhr University of Bochum Diabetic Foot July 2011 Phase 3
NCT01119105 Nabriva Therapeutics AG Bacterial Infections|Infection May 2010 Phase 2
NCT00175370 University of British Columbia Staphylococcal Infections September 2000
NCT00324922 University of Washington Osteomyelitis|Methicillin-resistant Staphylococcus Aureus May 2006
NCT01419184 Cubist Pharmaceuticals LLC Staphylococcal Skin Infections August 2011 Phase 4
NCT01775397 Astellas Pharma Europe Ltd.|Cubist Pharmaceuticals LLC|Astellas Pharma Inc Clostridium Difficile November 2012 Phase 4
NCT02202135 AstraZeneca|Forest Laboratories Complicated Skin and Soft Tissue Infection June 2014 Phase 3
NCT01499277 AstraZeneca|Forest Laboratories Complicated Skin and Soft Tissue Infection May 2012 Phase 3
NCT02218372 Astellas Pharma Europe B.V.|Merck Sharp & Dohme Corp.|Astellas Pharma Inc Clostridium Difficile-associated Diarrhea (CDAD) October 30, 2014 Phase 3
NCT00454272 Sanofi Infection|Febrile Neutropenia January 2005 Phase 4
NCT01626560 Hospital Universitario Evangelico de Curitiba Cellulitis July 2012 Phase 4
NCT03221023 University of British Columbia Vancomycin|Implantable Neural Stimulator|Deep Brain Stimulation|Surgical Site Infection September 15, 2017 Phase 2|Phase 3
NCT01175707 Cubist Pharmaceuticals LLC Complicated Skin or Skin Structure Infection July 2010 Phase 4
NCT00427076 Rabin Medical Center Staphylococcal Infections|Meningitis|Sepsis|Pneumonia June 2007 Phase 3
NCT00107952 Theravance Biopharma Antibiotics, Inc. Bacterial Pneumonia February 2005 Phase 3
NCT00124020 Theravance Biopharma Antibiotics, Inc. Bacterial Pneumonia January 2005 Phase 3
NCT00091819 Theravance Biopharma Antibiotics, Inc. Staphylococcal Skin Infection January 2005 Phase 3
NCT00107978 Theravance Biopharma Antibiotics, Inc. Staphylococcal Skin Infection February 2005 Phase 3
NCT02179658 Astellas Pharma Inc Clostridium Difficile May 2014 Phase 3
NCT00314951 Optimer Pharmaceuticals LLC Clostridium Infections|Diarrhea May 2, 2006 Phase 3
NCT01811732 Melinta Therapeutics, Inc. Skin and Subcutaneous Tissue Bacterial Infections April 2013 Phase 3
NCT01984684 Melinta Therapeutics, Inc. Skin and Subcutaneous Tissue Bacterial Infections|Skin Structures and Soft Tissue Infections May 2014 Phase 3
NCT00543608 Arpida AG Hospital-Acquired Pneumonia|Ventilator-Associated Pneumonia|Health-Care-Associated Pneumonia November 2007 Phase 2
NCT00296049 Wake Forest University Health Sciences|National Cancer Institute (NCI) Infection|Neutropenia|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific July 2005
NCT02027532 University of Tennessee Infection|Closed Fractures October 2009
NCT00430937 Novartis Pharmaceuticals|Novartis Skin Diseases, Infectious|Soft Tissue Infections April 2006 Phase 3
NCT00468728 Optimer Pharmaceuticals LLC Clostridium Infections|Diarrhea October 4, 2006 Phase 3
NCT00424190 Forest Laboratories Bacterial Infections February 2007 Phase 3
NCT00967941 CAMC Health System MRSA Infections August 2007 Phase 4
NCT01133600 Clinical Alliance for Research & Education - Infectious Diseases, LLC.|Cubist Pharmaceuticals LLC Diabetic Foot August 2010 Phase 4
NCT00150852 University Hospital, Geneva Wound Infection September 2004 Phase 2
NCT00572559 Pfizer Pneumonia, Ventilator-Associated November 2002 Phase 4
NCT02227446 Major Extremity Trauma Research Consortium Post Operative Surgical Site Infection October 2014 Phase 3
NCT00251017 National Taiwan University Hospital|Department of Health, Executive Yuan, R.O.C. (Taiwan) Adverse Effects July 2005
NCT01085760 Mayo Clinic|PSC Partners Seeking a Cure Foundation Primary Sclerosing Cholangitis February 2010 Phase 1
NCT01287832 St. John Health System, Michigan|Henry Ford Health System|Cubist Pharmaceuticals LLC Bacteremia June 2011 Phase 4
NCT02092935 Summit Therapeutics|Wellcome Trust Clostridium Difficile Infection April 2014 Phase 2
NCT02951702 St. Luke's Hospital, Chesterfield, Missouri Clostridium Difficile Infection|Prophylaxis|Vancomycin November 2016 Phase 4
NCT01252719 The Medicines Company Wound Infection|Abscess|Systemic Inflammation|Cellulitis December 2010 Phase 3
NCT01252732 The Medicines Company Wound Infection|Abscess|Systemic Inflammation|Cellulitis December 2010 Phase 3
NCT03107169 Universidad Autonoma de Nuevo Leon Clostridium Difficile Infection February 1, 2015
NCT02355938 Baylor College of Medicine|Cubist Pharmaceuticals LLC Clostridium Difficile|Spinal Cord Injury February 2014 Phase 4
NCT00911573 Wyeth is now a wholly owned subsidiary of Pfizer Skin Diseases|Infection August 2011 Phase 3
NCT02787057 Peking University First Hospital Peritoneal Dialysis Associated Peritonitis November 2012
NCT00167986 Wyeth is now a wholly owned subsidiary of Pfizer Escherichia Coli Infections|Klebsiella Infections January 2005 Phase 4
NCT01196169 Mountain Home Research & Education Corporation|East Tennessee State University|Cubist Pharmaceuticals LLC Staphylococcal Infections|Methicillin-resistant Staphylococcus Aureus October 2010 Phase 4
NCT03105479 Actelion Clostridium Difficile Infection April 14, 2017 Phase 2|Phase 3
NCT00423657 Forest Laboratories Bacterial Infections March 2007 Phase 3
NCT00811980 University of Utah|Pfizer Sepsis January 2009
NCT01363271 Pfizer|University of Maryland|Lodise & Lodise, LLC Complicated Skin and Structure Infection|Nosocomial Pneumonia May 2011 Phase 4
NCT00384527 Romark Laboratories L.C. Clostridium Infections December 2006 Phase 3
NCT02411331 University Hospital, Clermont-Ferrand|Centre Jean Perrin|CHG Jacques Lacarin (Vichy)|CH Henri Mondor (Aurillac)|Hôpital Nord (Saint-Etienne)|University Hospital, Grenoble|CH de Chambéry|Hôpital de la Croix-Rousse|Centre Leon Berard Lock Solution|Catheter Related Blood Stream Infections|Central Venous Catheter Infection|Intravenous Drug Delivery Systems|Coagulase-negative Staphylococci Infection March 2015
NCT02996487 William Beaumont Hospitals Clostridium Difficile Infection December 2016 Phase 4
NCT03030248 Medical College of Wisconsin|The Jackson Laboratory for Genomic Medicine Clostridium Difficile Infection June 1, 2017 Phase 4
NCT03137173 Basilea Pharmaceutica|Department of Health and Human Services Acute Bacterial Skin and Skin Structure Infections June 2017 Phase 3
NCT01669980 Forest Laboratories Infections|Pneumonia October 2012 Phase 4
NCT01860469 University of Saskatchewan Patients Undergoing Open Hernia Repair|Patients Undergoing Ventral or Inguinal Hernia Repair June 2013 Phase 2|Phase 3
NCT00228410 Wyeth is now a wholly owned subsidiary of Pfizer Skin Diseases, Infectious November 2002 Phase 3
NCT00304811 VA Medical Center, Houston|Baylor College of Medicine Staphylococcus Aureus January 2006 Phase 4
NCT02774382 Hvidovre University Hospital Clostridium Difficile September 2016 Phase 3
NCT00772447 AstraZeneca Skin Diseases|Infectious September 2008 Phase 3
NCT01431339 Durata Therapeutics Inc., an affiliate of Allergan plc Abscess|Wound Infection|Surgical Site Infection|Cellulitis July 2011 Phase 3
NCT01339091 Durata Therapeutics Inc., an affiliate of Allergan plc Abscess|Wound Infection|Surgical Site Infection|Cellulitis March 2011 Phase 3
NCT01191840 Duke University|National Institutes of Health (NIH) Bacteremia February 2011 Phase 2
NCT01952834 Medical College of Wisconsin Coronary Artery Disease June 2013 Phase 4
NCT00915967 Oregon Health and Science University Surgical Wound Infections July 2009
NCT00945152 Robert S Berman MD Bacterial Infections|Wounds July 2011 Phase 2
NCT02667418 VA Office of Research and Development Clostridium|Difficile|Fidaxomicin|Vancomycin December 21, 2015 Phase 4
NCT00035425 Pfizer Febrile Neutropenia November 2001 Phase 3
NCT02307006 University of Cincinnati|Forest Laboratories Surgical Site Infection January 2015 Phase 4
NCT02057198 Duke University C. Difficile|Diarrhea|Enterocolitis February 2014
NCT01184872 Novartis Pharmaceuticals|Novartis Infections March 2010 Phase 3
NCT00442832 Theravance Biopharma Antibiotics, Inc. Staphylococcal Skin Infection December 2006 Phase 2
NCT01645735 Forest Laboratories|AstraZeneca Infections October 2012 Phase 4
NCT02732327 Forest Laboratories Neoplasms|Febrile Neutropenia May 17, 2016 Phase 2
NCT02464020 University of Minnesota - Clinical and Translational Science Institute Primary Sclerosing Cholangitis|Inflammatory Bowel Disease July 2015 Phase 4
NCT01549613 University of Cincinnati Cellulitis|Skin Infections May 2012 Phase 4
NCT00612469 Universidade Federal do Ceara Dental Caries October 2005
NCT01537666 Savara Inc.|INC Research Limited Healthy|Cystic Fibrosis November 2011 Phase 1
NCT01198509 New York University School of Medicine|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|Memorial Sloan Kettering Cancer Center Rheumatoid Arthritis|Psoriatic Arthritis|Periodontal Disease January 2010
NCT01918813 Chikara Tashiro|Hyogo College of Medicine Inflammatory Bowel Disease|Hepatobiliary Disease|Pancreas Disease November 2009
NCT02478710 Wright State University Pneumonia, Ventilator-Associated June 2015 Phase 4
NCT01283581 Melinta Therapeutics, Inc. Skin and Subcutaneous Tissue Bacterial Infections January 2011 Phase 2
NCT02743234 University of Aarhus Clostridium Difficile Infection April 2016 Phase 3
NCT02582203 Wayne State University|Henry Ford Hospital|St. John Providence Health System|Detroit Medical Center|Forest Laboratories Skin Diseases, Infectious|Staphylococcal Skin Infections February 2012 Phase 4
NCT02801656 Memorial University of Newfoundland Clostridium Difficile July 2016 Phase 3
NCT01819935 Pfizer Pneumonia December 2012
NCT02570477 Chinese University of Hong Kong Clostridium Difficile Infection January 2015
NCT02660346 Sharp HealthCare Bacteremia November 2015 Phase 4
NCT01922011 Cubist Pharmaceuticals LLC Acute Hematogenous Osteomyelitis September 13, 2013 Phase 3
NCT01878643 Stony Brook University Respiratory Infection|Bacterial Resistance|Respiratory Failure December 2001 Early Phase 1
NCT00084266 Pfizer Methicillin Resistant Staphylococcus Aureus (MRSA) October 2004 Phase 4
NCT02590523 Panhandle Eye Group, LLP Intracameral Antibiotics|Cataract Surgery|Phacoemulsification|Endophthalmitis|Vancomycin|Moxifloxacin January 2018
NCT00871104 Juan A. Arnaiz|Hospital Clinic of Barcelona Infective Endocarditis July 2009 Phase 4
NCT01222702 Actelion Clostridium Difficile Infection January 25, 2011 Phase 2
NCT02426918 Debiopharm International SA Bacterial Infections May 2015 Phase 2
NCT00818766 Brigham and Women's Hospital Antibiotic Prophylaxis March 2008
NCT01798537 Rambam Health Care Campus Bacteremia Associated With Intravascular Line|Ventilator Associated Pneumonia|Bacteremia June 2013 Phase 2|Phase 3
NCT01594827 Michael Boyle|Case Western Reserve University|Cystic Fibrosis Foundation Therapeutics|Johns Hopkins University Cystic Fibrosis October 2012 Phase 2
NCT01598311 Cubist Pharmaceuticals LLC Clostridium Difficile Infection May 2012 Phase 3
NCT01597505 Cubist Pharmaceuticals LLC Clostridium Difficile Infection May 16, 2012 Phase 3
NCT02241421 Maastricht University Medical Center|Top Institute Food and Nutrition Obesity|Insulin Resistance April 2012
NCT01372371 Ganga Hospital Infection June 2011
NCT02037295 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) Obesity January 8, 2014 Phase 1
NCT02641236 Dana-Farber Cancer Institute Hematopoietic Stem Cell Transplantation (HSCT)|Acute GVH Disease March 2016 Phase 2
NCT01633762 University Hospital, Gentofte, Copenhagen|University of Copenhagen|Steno Diabetes Center|Department of clinical microbiology, Rigshospitalet, Copenhagen Diabetes|Obesity|Osteoporosis|Inflammation April 2012 Early Phase 1
NCT01085591 Cubist Pharmaceuticals LLC Clostridium Difficile Infection|Diarrhea April 2010 Phase 2
NCT03069976 Cliniques universitaires Saint-Luc- Université Catholique de Louvain Primary Sclerosing Cholangitis|Autoimmune Hepatitis|Overlap Syndrome January 2016
NCT00062647 Theravance Biopharma Antibiotics, Inc. Gram-Positive Bacterial Infections August 2003 Phase 2
NCT00037050 Pfizer Bacterial Infections|Gram-Positive Bacterial Infections|Bacteremia April 2002 Phase 3
NCT03181932 Savara Inc. MRSA|Cystic Fibrosis September 15, 2017 Phase 3
NCT00003805 European Organisation for Research and Treatment of Cancer - EORTC Bone Marrow Suppression|Fever, Sweats, and Hot Flashes|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific November 1997 Phase 3
NCT02857582 Per Hellström|Karolinska Institutet|Region Gävleborg|Uppsala University Clostridium Difficile October 2014 Phase 2
NCT02926846 Alice Ho Miu Ling Nethersole Hospital Peritonitis|Kidney Failure March 2014 Phase 4
NCT03157388 University of Aarhus Alcoholic Hepatitis June 1, 2017
NCT02865616 NuBiyota Clostridium Difficile Infection September 2016
NCT01734694 Henry Ford Health System Health Care Associated Pneumonia|Osteomyelitis/Septic Arthritis|Endocarditis|Bacteremia|Acute Bacterial Skin and Skin Structure Infections October 2011 Phase 4
NCT02285140 Hamilton Health Sciences Corporation|The Physicians' Services Incorporated Foundation Thoracic Surgery|Antibiotic Prophylaxis April 2015
NCT00228982 Basilea Pharmaceutica Skin Diseases, Infectious|Skin Diseases, Bacterial|Staphylococcal Skin Infections October 2004 Phase 3
NCT00426933 Cubist Pharmaceuticals LLC Soft Tissue Infections January 2007 Phase 2
NCT00925093 Aarhus University Hospital Neurosurgery September 2011 Phase 1
NCT00108433 Pfizer Bacteremia|Gram-Positive Bacterial Infections September 2005 Phase 3
NCT00210899 Basilea Pharmaceutica Skin Diseases, Infectious|Skin Diseases, Bacterial|Staphylococcal Skin Infections September 2005 Phase 3
NCT01746095 Savara Inc.|Synteract, Inc.|Cystic Fibrosis Foundation Therapeutics Cystic Fibrosis March 2013 Phase 2
NCT00087490 Pfizer Skin/Soft Tissue Infections|Methicillin Resistant Staphylococcus Aureus (MRSA) October 2004 Phase 4
NCT01942447 University Hospital Tuebingen Clostridium Difficile|Clostridium Difficile Infection October 2013
NCT02340182 W.J. Wiersinga, MD, PhD|ZonMw: The Netherlands Organisation for Health Research and Development|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Healthy|Sepsis March 2013
NCT02456974 University Hospital, Ghent|University Hospital, Antwerp|Queen Fabiola Children's University Hospital, Brussels Pharmacokinetics|Amoxicillin-clavulanate|Piperacillin-tazobactam|Vancomycin May 2012
NCT02148601 Catholic University of the Sacred Heart Recurrent C. Difficile Infection. July 2013 Phase 2
NCT03053505 Sejtterapia Kozpont Kft.|University of Debrecen|Kenézy Gyula Korhaz es Rendelointezet|Szabolcs-Szatmar-Bereg Megyei Korhaz es Egyetemi Oktatokorhaz|Miskolci Semmelweis Korhaz es Egyetemi Oktatokorhaz|Bacs-Kiskun Megyei Korhaz|UD-Genomed Kft. Clostridium Difficile Infection January 2017
NCT02127749 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Endotoxemia June 2014
NCT03036826 University Hospital Tuebingen Acute Kidney Insufficiency|Anti-Infective Agent Toxicity October 2017
NCT02968693 Yulin Orthopedics Hospital of Chinese and Western Medicine Osteomyelitis April 2011
NCT02301221 Jinling Hospital, China Slow Transit Constipation March 2015 Phase 2
NCT00770341 Merck Sharp & Dohme Corp. Staphylococcal Infection September 2008 Phase 3
NCT02609646 Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva Critical Illness|Infection January 2016
NCT02216227 Iowa City Veterans Affairs Medical Center Surgical Site Infection April 2014
NCT01232595 Novartis Pharmaceuticals|Novartis Moderate Clostridium Difficile Infection October 2010 Phase 2
NCT01592032 Clinica Universidad de Navarra, Universidad de Navarra|University of Navarrra Hospital (Clinica Universitaria) Catheter-Related Infections|Bacteremia. May 2012 Phase 4
NCT02208063 Theravance Biopharma R & D, Inc.|Theravance Biopharma Antibiotics, Inc. Bacteremia December 2014 Phase 3
NCT02573064 Maimónides Biomedical Research Institute of Córdoba Acinetobacter Infections January 2010
NCT00077675 Theravance Biopharma Antibiotics, Inc. Infections, Gram-Positive Bacterial February 2004 Phase 2
NCT00061633 Theravance Biopharma Antibiotics, Inc. Infections, Gram-Positive Bacterial|Abscess|Burns|Cellulitis|Ulcer|Wound Infections June 2003 Phase 2
NCT01400867 Forest Laboratories|AstraZeneca Infections, Pediatrics December 2011 Phase 2|Phase 3
NCT01828892 Jinling Hospital, China Low-output External Gastrointestinal Fistula March 2014
NCT02686645 Queen Elizabeth II Health Sciences Centre Clostridium Difficile Infection December 2016 Phase 2|Phase 3
NCT02466698 Lawson Health Research Institute|London Health Sciences Centre Clostridium Difficile August 2016 Phase 2|Phase 3
NCT01820026 University of Roma La Sapienza Cirrhosis December 2012 Phase 4
NCT00396578 Stony Brook University|Nektar Therapeutics Ventilator Associated Pneumonia|Respiratory Infection|Tracheobronchitis August 2003 Phase 2
NCT00529282 Basilea Pharmaceutica Fever|Neutropenia|Gram-positive Bacterial Infections|Pseudomonas Infection October 2007 Phase 3
NCT02168816 Loyola University Osteomyelitis June 2014 Phase 2
NCT02344511 Durata Therapeutics International BV (an Affiliate of Actavis, Inc.)|Durata Therapeutics Inc., an affiliate of Allergan plc Osteomyelitis March 2016 Phase 3
NCT02701595 University Hospital, Tours Infective Endocarditis March 2016 Phase 3
NCT02463747 Tel-Aviv Sourasky Medical Center Fever|Febrile Neutropenia June 2015 Phase 4
NCT02618187 Seres Therapeutics, Inc. Ulcerative Colitis December 2015 Phase 1
NCT02504554 Arizona State University|Northern Arizona University|University of Arizona|University of Minnesota - Clinical and Translational Science Institute Gastrointestinal Problems|Autism Spectrum Disorders July 2014 Phase 1|Phase 2
NCT01104662 Cubist Pharmaceuticals LLC Complicated Skin and Skin Structure Infections|S. Aureus Bacteremia|Renal Impairment April 2010 Phase 4
NCT02154061 Emory University Influenza April 2015
NCT00435305 University Hospital Tuebingen Pneumonia|Bacteremia November 2006 Phase 4
NCT02765256 University of Pennsylvania|Children's Hospital of Philadelphia|Crohn's and Colitis Foundation Crohn's Disease August 2016 Phase 2
NCT02730962 University of Minnesota - Clinical and Translational Science Institute Pre-Diabetes June 2016 Phase 2
NCT00462878 PETHEMA Foundation Allogenic Blood Stem Cell Transplantation|Febrile Neutropenia November 2002
NCT02384200 University of California, San Diego|Mayo Clinic|University of British Columbia|The Cleveland Clinic|Duke University|Ohio State University|Dartmouth-Hitchcock Medical Center|Vanderbilt University|New York University Nephrolithiasis|Urinary Tract Infections March 2015 Phase 4
NCT00451373 National Taiwan University Hospital Acute Renal Failure|Sepsis|Postoperative July 2006
NCT01757236 University Hospital, Tours|Pfizer|International Clinical Trials Association Hip Prosthetic Joint Infection October 2012 Phase 2
NCT00428844 Cubist Pharmaceuticals LLC Osteomyelitis January 2007 Phase 2
NCT02701608 University Hospital, Tours Infective Endocarditis March 2016 Phase 3
NCT01792804 Heinrich-Heine University, Duesseldorf|German Research Foundation Staphylococcus Aureus Infection December 2013 Phase 3
NCT00445094 Merck Sharp & Dohme Corp. Infection|Pneumonia November 2006 Phase 4
NCT00050401 AstraZeneca Pneumonia July 2002 Phase 3
NCT00355602 University of Dundee|Tenovus Scotland Colitis, Ulcerative July 2006
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 0.6731 mL 3.3654 mL 6.7307 mL
5 mM 0.1346 mL 0.6731 mL 1.3461 mL
10 mM 0.0673 mL 0.3365 mL 0.6731 mL
Animal Administration
[3]

Mouse: One set of experiments is performed in which infected mice are treated with vancomycin (50 mg/kg) daily for 1, 2, 3, or 5 days and are observed for 21 days postinfection or with vancomycin (20 mg/kg) daily for either 5 or 10 days and monitoring for 15 days postinfection[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

1485.72

Formula

C₆₆H₇₆Cl₃N₉O₂₄

CAS No.

1404-93-9

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: 24 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Vancomycin hydrochloride
Cat. No.:
HY-17362
Quantity: